The International Conference on Harmonization finalizes Q&A document on APIs.
The International Conference on Harmonization (ICH) announced on June 19, 2015 that Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Questions and Answers has reached Step 4 of the process and now enters into Step 5, the implementation stage. The Q&A document addresses confusion regarding interpretation of the Q7 guideline and aims to harmonize expectations during inspections of both small molecules and biotech APIs.
Topics clarified in the Q&A document are varied. The following are some of the answers ICH provides:
Other topics discussed include production and in-process controls; storage and distribution; laboratory controls; validation; change control; and contract manufacturers.
The Q7 Q&A document can be found on ICH’s guideline webpage.
Source: ICH.org
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.